The development of the Metacognitions About Boredom Scale (MABS) and its role in problematic social media use
Journal of Behavioral Addictions · 2026
DOI: 10.1556/2006.2025.00499 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Behavioral Addictions, 2026. Verfasst von Mehdi Akbari und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Clinical Psychology, Faculty of Psychology and Education, Kharazmi University, Tehran, Iran. Hauptthemen laut MEDLINE: Boredom, Social Media, Psychometrics, Internet Addiction Disorder. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Boredom is a universal affective–cognitive state arising from unmet needs for meaningful engagement. Although unpleasant, boredom can inspire creativity and purposeful action or trigger maladaptive behaviors such as problematic social media use (PSMU). The present study developed and validated the Metacognitions About Boredom Scale (MABS), a new instrument designed to assess positive and negative metacognitions about boredom.
Methods
The research comprised two studies. Study 1 involved mixed-methods item generation and large-scale validation among Iranian adults ( N = 1,021; 58.0% females; mean age = 39.4 years), employing exploratory and confirmatory factor analyses. Study 2 involved at-risk individuals with problematic social media use ( N = 234); bifactor and ROC analyses were conducted to determine an optimal cut-off score for positive and negative metacognitions about boredom.
Results
Study 1 supported a stable two-factor structure of positive and negative metacognitions about boredom, confirmed through both exploratory and confirmatory analyses. Both subscales demonstrated excellent reliability, strong test–retest stability, and full measurement invariance across gender and age. Incremental validity analyses showed that the MABS predicted boredom and PSMU beyond general metacognitions. Study 2 confirmed the bifactor model, and ROC analysis indicated an optimal cut-off of ≥32 on the negative belief subscale for distinguishing individuals at risk of boredom-driven PSMU, yielding 95.3% sensitivity and 97.1% specificity.
Conclusions
The MABS is a valid, theory-based tool assessing boredom-related metacognitions and identifying cognitive risks for maladaptive online behaviors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1Department of Clinical Psychology, Faculty of Psychology and Education, Kharazmi University, Tehran, Iran.
- 2Department of Psychology, Faculty of Education and Psychology, Alzahra University, Tehran, Iran.
- 3Flinders University Institute for Mental Health and Wellbeing, College of Education, Psychology and Social Work, Flinders University, Bedford Park, SA, Australia.
- 4Institute of Psychology, ELTE Eotvos Lorand University, Budapest, Hungary.
- 5Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar, Gibraltar.
- 6Nottingham Institute of Psychology, Nottingham Trent University, Nottingham, UK.
ORCID-Profile: Mehdi Akbari, Roya Forootan, Zahra Tabar, Zsolt Demetrovics, Mark D Griffiths
Zitieren
APA
Akbari, M., Forootan, R., Tabar, Z., Demetrovics, Z., & Griffiths, M. D. (2026). The development of the Metacognitions About Boredom Scale (MABS) and its role in problematic social media use. Journal of Behavioral Addictions. https://doi.org/10.1556/2006.2025.00499
Vancouver
Akbari M, Forootan R, Tabar Z, Demetrovics Z, Griffiths MD. The development of the Metacognitions About Boredom Scale (MABS) and its role in problematic social media use. Journal of Behavioral Addictions. 2026. doi:10.1556/2006.2025.00499
BibTeX
@article{Akbari2026,
author = {Akbari, Mehdi and Forootan, Roya and Tabar, Zahra and Demetrovics, Zsolt and Griffiths, Mark D},
title = {The development of the Metacognitions About Boredom Scale (MABS) and its role in problematic social media use},
journal = {Journal of Behavioral Addictions},
year = {2026},
doi = {10.1556/2006.2025.00499}
}
EUVIMED